This longitudinal, randomized controlled trial (n=0, withdrawn) compares the efficacy of Electroconvulsive Therapy (ECT) and intranasal esketamine in patients with Treatment-Resistant Depression (TRD).
Randomised, parallel-group trial comparing intranasal esketamine (twice weekly, up to 8 sessions) versus ECT (three times weekly, up to 12 sessions) in inpatients with treatment-resistant depression at Medical University Innsbruck.
Primary aims include effectiveness for depressive symptoms and effects on brain connectivity and structure assessed by functional MRI; treatment period is up to 4 weeks with imaging and clinical follow-up.
Intranasal esketamine administered twice weekly for up to 4 weeks (max 8 sessions) or until remission (MADRS <10).
Up to 8 intranasal esketamine sessions over 4 weeks or until MADRS <10.
Electroconvulsive therapy administered thrice weekly for up to 4 weeks (max 12 sessions) or until remission (MADRS <10).
Up to 12 ECT treatments over 4 weeks or until MADRS <10.